Kimberly Babson, PhD

Pooled Analysis From 12-Week Randomized, Controlled Studies of Solriamfetol in the Treatment of Excessive Daytime Sleepiness in Participants With Obstructive Sleep Apnea or Narcolepsy

Background: Solriamfetol (formerly JZP-110), a dopamine and norepinephrine reuptake inhibitor, has been approved in the US (SunosiTM) to improve wakefulness in adults with excessive dayti...

Colin Shapiro , PhD, FRCPC, MBBCh;

Michelle Baladi , PhD;

Dandan Chen , MD, PhD;

Helene Emsellem , MD;

Michael Thorpy , MD, CHBC;

Kris Liu , PhD;

Paula Schweitzer , MD, PhD;

Kimberly Babson , PhD;

11/22/2019

Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants With Narcolepsy or Obstructive Sleep Apnea With a History of Depression

Background: Depression is commonly comorbid with narcolepsy and obstructive sleep apnea (OSA). Solriamfetol (SunosiTM), a dopamine/norepinephrine reuptake inhibitor, has been approved in ...

Lawrence Lee , PhD;

Russell 1022962 , PhD;

Atul Malhotra , MD;

Paula Schweitzer , MD, PhD;

Kimberly Babson , PhD;

Shay Bujanover , MD;

Kingman Strohl , MD;

Ruth Benca , MD, PhD;

11/22/2019